Literature DB >> 21872228

Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up.

Miriam Hudecova1, Jan Holte, Matts Olovsson, Anders Larsson, Christian Berne, Inger Sundstrom-Poromaa.   

Abstract

OBJECTIVE: To examine the prevalence of the metabolic syndrome (MetS) according to the scientific statement of the American Heart Association and the US National Cholesterol Education Program/Adult Treatment Panel III in middle-aged Swedish women previously diagnosed with polycystic ovary syndrome (PCOS) in comparison with age-matched healthy controls.
DESIGN: Long-term follow-up study.
SETTING: Department of Obstetrics and Gynecology, Uppsala University. PATIENT(S): Eighty-four women diagnosed with PCOS between 1987 and 1995; and 87 controls randomly selected from the general population. INTERVENTION(S): Anthropometric measurements and blood tests. MAIN OUTCOME MEASURE(S): Body mass index, waist circumference, blood pressure, lipids, and glucose. RESULT(S): The prevalence of MetS in women with PCOS (mean ± SD age, 43.0 ± 5.8 years) was 23.8% and in controls was 8.0%, and it did not differ according to PCOS phenotype at the index assessment (polycystic ovaries [PCO], oligomenorrhea, and hirsutism: 10 [22.7%]; PCO and oligomenorrhea: 8 [22.2%]) or according to the persistence of PCOS features at follow-up (persisting PCOS: 25.8%; resolved PCOS: 16.7%). CONCLUSION(S): The MetS occurred more often in patients with PCOS than in controls and did not depend on phenotypic presentation at the index assessment or the persistence of PCOS at follow-up.
Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21872228     DOI: 10.1016/j.fertnstert.2011.08.006

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Dysglycemia screening with oral glucose tolerance test in adolescents with polycystic ovary syndrome and relationship with obesity.

Authors:  Jyotsna Gupta; Zoltan Antal; Elizabeth Mauer; Linda M Gerber; Anjile An; Marisa Censani
Journal:  BMC Endocr Disord       Date:  2022-07-16       Impact factor: 3.263

Review 2.  Metabolic syndrome, hypertension, and hyperlipidemia in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Bulent Yilmaz; Priyathama Vellanki; Baris Ata; Bulent Okan Yildiz
Journal:  Fertil Steril       Date:  2018-01-11       Impact factor: 7.329

Review 3.  Angiotensin-converting enzymes play a dominant role in fertility.

Authors:  Pei-Pei Pan; Qi-Tao Zhan; Fang Le; Ying-Ming Zheng; Fan Jin
Journal:  Int J Mol Sci       Date:  2013-10-21       Impact factor: 5.923

4.  Association of leptin and insulin resistance in PCOS: A case-controlled study.

Authors:  Bahia Namavar Jahromi; Mohammad Hassan Dabaghmanesh; Mohammad Ebrahim Parsanezhad; Faranak Fatehpoor
Journal:  Int J Reprod Biomed       Date:  2017-07

Review 5.  Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Jamal Hallajzadeh; Maliheh Khoramdad; Nahid Karamzad; Amir Almasi-Hashiani; Ali Janati; Erfan Ayubi; Reza Pakzad; Mark J M Sullman; Saeid Safiri
Journal:  J Cardiovasc Thorac Res       Date:  2018-05-28

6.  Trend of Cardio-Metabolic Risk Factors in Polycystic Ovary Syndrome: A Population-Based Prospective Cohort Study.

Authors:  Fahimeh Ramezani Tehrani; Seyed Ali Montazeri; Farhad Hosseinpanah; Leila Cheraghi; Hadi Erfani; Maryam Tohidi; Fereidoun Azizi
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

7.  Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis.

Authors:  V Wekker; L van Dammen; A Koning; K Y Heida; R C Painter; J Limpens; J S E Laven; J E Roeters van Lennep; T J Roseboom; A Hoek
Journal:  Hum Reprod Update       Date:  2020-11-01       Impact factor: 15.610

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.